SCHEMBL2089751

SCHEMBL2089751

CC(C)(CO)NC(=O)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.66
MAOB P27338 1/20 0.61
NR4A2 P43354 2/20 0.60
GPR132 Q9UNW8 2/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
NR1H4 Q96RI1 1/20 0.58
PTPN1 P18031 1/20 0.56
GUSB P08236 1/20 0.56
NR4A1 P22736 1/20 0.55
NR4A3 Q92570 1/20 0.55
SRD5A2 P31213 1/20 0.54
FAAH O00519 1/20 0.54
CNR2 P34972 1/20 0.54
TSHR P16473 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13701690 0.88 SMPD1 (0.71) SMPD1MAOBNR4A2GPR132MEN1
SCHEMBL2089324 0.86 HDAC3 (0.59) MAOBNR4A2MEN1KMT2ANR1H4
SCHEMBL9565396 0.82 LMNA (0.50) SMPD1MEN1KMT2ANR1H4SMN1; SMN2
SCHEMBL13702365 0.81 SMPD1 (0.76) SMPD1MAOBNR4A2GPR132MEN1
SCHEMBL6301076 0.81 NPC1 (0.57) MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL27939013 0.81 LMNA (0.49) SMPD1MAOBGPR132KMT2ASMN1; SMN2
SCHEMBL21616251 0.80 SMPD1 (0.74) SMPD1MAOBNR4A2GPR132MEN1
SCHEMBL1608032 0.80 SMPD1 (1.00) SMPD1MAOBNR4A2GPR132MEN1
SCHEMBL7410475 0.80 SMPD1 (0.78) SMPD1MAOBNR4A2GPR132MEN1
SCHEMBL2759010 0.79 NPC1 (0.61) KMT2ACNR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161331-A1 Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-07-03 US claimed
US-7863450-B2 Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2011-01-04 US disclosed
US-20080161331-A1 Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161331-A1 Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses NR1H3, NR1I3, NR1I2 SMPD1 4763/4885MAOB 771/4885NR4A2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.